Key result
Serum adipsin was significantly associated with thin-cap fibroatheromas (OR 1.290; 95% CI 1.048-1.589; P=0.016) and showed moderate diagnostic accuracy (AUC 0.710) in patients with CAD.
Why the study?
Early identification of vulnerable plaques is important to reduce acute coronary events in CAD, but the relationship between adipsin and plaque vulnerability was unknown.
Is serum adipsin associated with plaque vulnerability determined by optical coherence tomography in patients with coronary artery disease?
Cross-Sectional (n=99)
Is serum adipsin associated with plaque vulnerability determined by optical coherence tomography in patients with coronary artery disease?
Odds Ratio: 1.29 (95% CI 1.048–1.589)
p-value: p=0.016
Higher serum adipsin levels are significantly associated with increased plaque vulnerability and the presence of thin-cap fibroatheromas in patients with coronary artery disease.
Should not yet change TCFA assessment in CAD; leaves open adipsin's incremental value as a circulating vulnerability marker.
BACKGROUND: Early identification of vulnerable plaques is important for patients with coronary artery disease (CAD) to reduce acute coronary events and improve their prognosis. We sought to examine the relationship between adipsin, an adipokine secreted from adipocytes, and plaque vulnerability in CAD patients. METHODS: A total of 103 plaques from 99 consecutive patients who underwent coronary angiography were assessed by optical coherence tomography. The serum level of adipsin was measured using enzyme-linked immunosorbent assay (ELISA). The accuracy of adipsin for detecting thin-cap fibroatheroma (TCFA) was determined by the area under the receiver operating characteristic curve (AUC). RESULTS: 21.2%, P=0.028) compared with the low adipsin group. Serum adipsin was found to be negatively correlated with fibrous cap thickness (ρ=-0.322, P=0.002), while it was positively correlated with average lipid arc (ρ=0.253, P=0.015), maximum lipid arc (ρ=0.211, P=0.044), lipid core length (ρ=0.241, P=0.021), lipid index (ρ=0.335, P=0.001), and vulnerability score (ρ=0.254, P=0.014). Furthermore, adipsin had a significant association with TCFAs (OR: 1.290, 95% CI: 1.048-1.589, P=0.016) in the multivariate analysis, while having a moderate diagnostic accuracy for TCFAs (AUC: 0.710, 95% CI: 0.602-0.817, P<0.001). CONCLUSIONS: Our findings suggest that serum adipsin is significantly and positively correlated with the incidence of TCFAs. The application of adipsin as a biomarker may offer improvement in the diagnosis of vulnerable plaques and clinical benefits for CAD patients.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2021) conducted a cross-sectional in Coronary artery disease (n=99). Serum adipsin vs. Low adipsin was evaluated on Thin-cap fibroatheroma (TCFA) (OR 1.290, 95% CI 1.048-1.589, p=0.016). Serum adipsin was significantly associated with thin-cap fibroatheromas (OR 1.290; 95% CI 1.048-1.589; P=0.016) and showed moderate diagnostic accuracy (AUC 0.710) in patients with CAD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: